Napo Pharm.Regs Share Discussion Threads

[monis] 24/4/2008 10:15

Up again today.

[monis] 23/4/2008 15:11

From recent update. Make of it what you will.


...Management have plans to raise additional funds, which include: the out-license of certain rights to crofelemer including the indications of CRO-HIV, CRO-IBS,CRO-ID and CRO-PED in the United States and other western territories; as well as certain rights to NP-500, in exchange for a licensing fee(s)...


...Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company."

... Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented:

"It is my firm belief that, the fall in the Company's share price places an
unrealistic value on Napo and disregards the recently announced trial results.



Of cause DYOR.

[monis] 23/4/2008 12:23

Seems to be moving up with each new buy.

[monis] 23/4/2008 11:50

Discovered these yesterday it looks to me like they have dropped too far. Could be a big rise on the cards.

[double6] 21/4/2008 19:55

We'll see in a week or two!

[wiganer] 17/4/2008 20:02

Funniest chart ever?

[sven2006] 17/4/2008 12:45

Hoodless


follow them and you'll end up broke, the name says it all.

[napoleon 14th] 29/2/2008 10:57

Hoodless offered me a bunch, so someone is unloading for whatever reason.

Phase III fast-track in the US is good news, but the chart is a pile of........


diarrhoea!

[zeca2] 16/10/2007 14:39

Pile in at these levels.

[zeca2] 19/12/2006 00:06

Yes, Im here. Looks good. Crofelmer will help millions.

[zchanl1] 07/12/2006 17:49

Anybody else here?...!

[zchanl1] 21/11/2006 22:39

Interesting meeting with Lisa Conte today at Nomura.

[zchanl1] 15/11/2006 09:54

Anyone else about at present??

[zchanl1] 13/11/2006 22:38

Highly selective target, the gastrointestinal mucosal chloride ion channel. Product sounds promising, with environmentally friendly and natural remedy type benefits. Huge market, also safe for kids. Like the sounds of this very much.

[currypasty] 31/7/2006 13:50

RNS Number:9592G
Napo Pharmaceuticals Inc
31 July 2006


For immediate release 31st July 2006


Napo Pharmaceuticals, Inc
("Napo" or "the Company")


First Day of Dealings on the Main Market of the London Stock Exchange



Napo Pharmaceuticals, Inc., (LSE: NAPL), which focuses on the development and
commercialisation of proprietary pharmaceuticals for the global marketplace in
collaboration with local partners, today announces that its shares have started
trading on the Main Market of the London Stock Exchange.


Company highlights:

* Napo's late stage proprietary gastro-intestinal compound, crofelemer, is
in various stages of clinical development for four distinct product
indications.
* One product in Phase 3, two in Phase 2 and one in Phase 1 clinical trials
* Four indications - AIDS diarrhoea, Irritable Bowel Syndrome (IBS), acute
infectious diarrhoea (traveller's diarrhoea and cholera) and paediatric
diarrhoea
* FDA fast-track status for AIDS diarrhoea and IBS products
* Extensive safety data on approximately 1500 patients across all
indications
* Global business model with multiple corporate partners covering all four
clinical indications in all countries
* Focus on profitability in Western markets and emerging economy populations
for large product volume and financial return
* Pipeline product for metabolic syndrome
* Strong management and Board experience with more than 10 drug regulatory
approvals worldwide
* Crofelemer sustainably harvested from medical rainforest plant - benefit
sharing contribution in place to recognise indigenous knowledge and
environmental responsibility.



Placing highlights:

* Placing and subscription proceeds of circa. #11.9M before expenses
* Placing price of 83 pence per share
* Market capitalisation at the placing price of circa. #35.8M
* Proceeds of the placing will be used to continue to progress the Company's
pipeline including product registration and launches



Nomura Code Securities Limited is acting as the sponsor, financial adviser and
broker.



Ms Lisa Conte, Chief Executive Officer of Napo Pharmaceuticals Inc, commented:

"As a global business we are delighted to join the Main Market of the London
Stock Exchange today. We have a strong and late-stage pipeline and will use the
proceeds of this placing to develop our products which will address large and
profitable western indications as well as global health needs afflicting huge
populations in emerging and developing economies. These activities will
generate multiple revenue streams from around the world."



For more information please contact:


Napo Pharmaceuticals, Inc

Lisa Conte, Chief Executive Officer (001) + 650 616 1902
www.napopharma.com

Buchanan Communications [phone]

Tim Anderson, Mary-Jane Johnson, Amy Rajendran

Nomura Code Securities Limited

Juliet Thompson [phone]



Disclaimer The Shares referenced in this announcement are not for distribution,
directly or indirectly, in or into the United States or to any US person as
defined in Regulation S under the US Securities Act of 1933, as amended
("Regulation S"). This announcement is not an offer of securities for sale into
the United States or elsewhere. The Shares described above have not been
registered under the US Securities Act of 1933, as amended (the "Securities
Act") and may not be offered or sold in the United States or to, or for the
account or benefit of, US persons (as such term is defined in Regulation S)
unless they are registered under the Securities Act or they are exempt from
registration under the Securities Act. No offer or sale of Regulation S
securities has been made or will be made in the United States. Hedging
transactions involving these securities may not be conducted unless in
compliance with the Securities Act.

[currypasty] 31/7/2006 13:50

Company highlights:

* Napo's late stage proprietary gastro-intestinal compound, crofelemer, is
in various stages of clinical development for four distinct product
indications.
* One product in Phase 3, two in Phase 2 and one in Phase 1 clinical trials
* Four indications - AIDS diarrhoea, Irritable Bowel Syndrome (IBS), acute
infectious diarrhoea (traveller's diarrhoea and cholera) and paediatric
diarrhoea
* FDA fast-track status for AIDS diarrhoea and IBS products
* Extensive safety data on approximately 1500 patients across all
indications
* Global business model with multiple corporate partners covering all four
clinical indications in all countries
* Focus on profitability in Western markets and emerging economy populations
for large product volume and financial return
* Pipeline product for metabolic syndrome
* Strong management and Board experience with more than 10 drug regulatory
approvals worldwide
* Crofelemer sustainably harvested from medical rainforest plant - benefit
sharing contribution in place to recognise indigenous knowledge and
environmental responsibility.



Placing highlights:

* Placing and subscription proceeds of circa. #11.9M before expenses
* Placing price of 83 pence per share
* Market capitalisation at the placing price of circa. #35.8M
* Proceeds of the placing will be used to continue to progress the Company's
pipeline including product registration and launches